ARTICLE | Company News
ALS Biopharma, Biohaven deal
October 5, 2015 7:00 AM UTC
Biohaven purchased from ALS Biopharma worldwide rights to IP covering more than 300 prodrugs. The companies said most of the prodrugs are NMEs that modulate glutamate. Biohaven plans to focus on devel...